GlassScriptPhysician profile
Priyanka Kakar
NPI 1205928959
$1,827.79
in general payments reported to CMS, 2019-2025
23 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $13.66 · 2022: $77.25 · 2023: $383 · 2024: $165 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.20 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $351.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $311.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $219.40 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $198.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $113.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $95.46 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $67.83 | 2019-2025 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.91 | 2025 | Caplyta |
| Abbott Laboratories | $56.75 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $51.25 | 2019-2025 | |
| Astellas Pharma US INC | $45.36 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $42.12 | 2023 | |
| Janssen Pharmaceuticals, INC | $30.56 | 2019 | |
| Pfizer INC. | $30.11 | 2019-2022 | |
| Dexcom, INC. | $23.35 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $19.90 | 2022 | |
| Heartflow, INC. | $18.83 | 2024 | |
| Corcept Therapeutics | $18.51 | 2025 | Korlym |
| Ethicon INC. | $17.46 | 2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $17.02 | 2019 | |
| Dynavax Technologies Corporation | $12.93 | 2022 | |
| Mylan Specialty L.P. | $12.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priyanka Kakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.